SHOX Duplication and Tall Stature in a Patient with Xq Deletion and Vascular Disease.

The anomalies of X chromosome are classified as numerical or structural. Concomitant structural anomalies in this chromosome that associate partial loss of its long arm with duplications in its short arm are uncommon. Only a few cases have been published and in most of them the reported patients present ovarian dysfunction, tall stature, and overdosage of the SHOX gene with locus Xp22.33. Considering these reports, we evaluated the case of a woman with a deletion in the long arm of the X chromosome, premature ovarian failure, tall stature, and multiple arterial vascular disease. With the aim to find a relationship between karyotype and phenotype, we explored associated anomalies in Xp and certified the overdosage of the SHOX gene in this case by MLPA. Also, taking into account the fact that the gene locus of the angiotensin-converting enzyme type 2 (ACE2) is located in Xp, our goal was to investigate the influence of this gene in the development of cardiovascular disease. The detection of the gene product of ACE2 by ELISA was undetectable. We have proposed that cytogenetic anomalies in X chromosome could contribute to decrease this protein synthesis in this gender.

Role of Renin-Angiotensin system and oxidative stress on vascular inflammation in insulin resistence model.

(1) This study aims to demonstrate the causal involvement of renin angiotensin system (RAS) and oxidative stress (OS) on vascular inflammation in an experimental model of metabolic syndrome (MS) achieved by fructose administration to spontaneously hypertensive rats (FFHR) during 12 weeks. (2) Chronic treatment with candesartan (C) (10 mg/kg per day for the last 6 weeks) or 4OH-Tempol (T) (10(-3) mmol/L in drinking water for the last 6 weeks) reversed the increment in metabolic variables and systolic blood pressure. In addition, chronic C treatment reverted cardiovascular remodeling but not T. (3) Furthermore, chronic treatment with C was able to completely reverse the expression of NF-κB and VCAM-1, but T only reduced the expression. C reduced the expression of proatherogenic cytokines as CINC2, CINC3, VEGF, Leptin, TNF-alpha, and MCP-1 and also significantly reduced MIP-3, beta-NGF, and INF-gamma in vascular tissue in this experimental model. T was not able to substantially modify the expression of these cytokines. (4) The data suggest the involvement of RAS in the expression of inflammatory proteins at different vascular levels, allowing the creation of a microenvironment suitable for the creation, perpetuation, growth, and destabilization of vascular injury.

Effect of nebivolol on cardiovascular changes associated with a rat model of insulin-resistance.

Nebivolol is a vasodilator that combines beta-adrenergic blocking activity with a relaxant effect on vascular smooth muscle cells (VSMC) mediated by the endothelial nitric oxide (NO) pathway. FFR provide a model of dietary-induced insulin-resistance syndrome, which has been used to study the pathophysiological mechanisms associated with this syndrome. Our main objective was to examine the effect of long-term administration of nebivolol on metabolic and cardiovascular variables in fructose-fed rats (FFR), a model in which an altered bioavailability of NO has been already described. Male Wistar rats were randomly assigned to 4 groups (n = 8 each): I. Control (C); II. Control + nebivolol (C+N): 1 mg/kg(-1) x day(-1) in drinking water during the last 4 weeks. III. FFR: rats receiving fructose in drinking water as a 10% (w/v) solution during 8 weeks, and IV. FFR+N: idem II plus III. During the 8 weeks experimental period, variations in systolic blood pressure (SBP), glucose tolerance test (GTT) and plasma thiobarbituric acid-reactive substances (TBARS) were assessed. At the end of this experimental period, rats were killed and heart and kidneys were excised for calculation of relative heart weight (RHW) and histological evaluation of lumen to media ratio (L/M) in renal arteries. Rats from FFR group increased their SBP and RHW, showed glucose intolerance and an increment in lipid peroxidation. Moreover, FFR showed vascular remodeling in renal arteries evidenced by changes in L/M. Although the metabolic changes were not reverted by the administration of nebivolol, this drug successfully decreased SBP, TBARS levels and reverted structural changes such as cardiac hypertrophy and renal arterial remodeling. Data demonstrate that nebivolol administration could participate in the reversion of cardiovascular structural changes associated with the insulin-resistance syndrome.

Proteoglycan production by vascular smooth muscle cells from resistance arteries of hypertensive rats.

Extracellular matrix (ECM) modifications in the vascular wall contribute to the narrowing of arteries in hypertension. Because direct evidence for the role of proteoglycans (PGs) in the pathological process of resistance-sized arteries has not already been demonstrated, we examined the effect of growth factors on secreted and membrane-bound PG synthesis by cultured mesenteric vascular smooth muscle cells (VSMC) from spontaneously hypertensive rats (SHR) and Wistar rats. After 48 hours of stimulation with angiotensin II (Ang II), platelet-derived growth factor (PDGF-BB), and 10% fetal calf serum (FCS) or 0.1% FCS as control, PG synthesis (in dpm/ng DNA) was evaluated in the medium (M-ECM) and in the cell layer (P-ECM) by a double-isotopic label method with both [(3)H]-glucosamine and [(35)S]-sodium sulfate, which are incorporated into all complex carbohydrates or only into sulfated disaccharides, respectively. VSMC from SHR displayed a significantly lower level of synthesis of M-ECM [(3)H]-PGs than those of Wistar rats in all the experimental groups, including the control group (0. 1% FCS), but no differences in M-ECM [(35)S] uptake were found in any case. In the P-ECM, Ang II was the only factor that produced a lesser effect on [(3)H]-glucosamine and a greater effect on [(35)S]-sodium sulfate uptakes in VSMC from SHR than from Wistar rats. The most prominent change seen in VSMC from SHR was an increased sulfation, assessed by [(35)S]/[(3)H] ratio, in nonstimulated cells and in response to 10% FCS and Ang II but not to PDGF-BB compared with VSMC from Wistar rats. These data indicate the existence of changes in PG modulation in the resistance vessels of SHR, which suggests that PGs may contribute to the development of structural and functional modifications in hypertensive states.

Cardiovascular kinin-generating capability in hypertensive fructose-fed rats.

OBJECTIVE: The hypertensive state is often associated with metabolic abnormalities, including glucose intolerance. Tissue kallikrein, a potent kinin-generating enzyme, is present in the vascular wall and heart tissue. High dietary fructose consumption is reported to induce hyperinsulinemia, hypertriglyceridemia and hypertension. The objective of the present study was to examine the status of kallikrein in vascular and cardiac tissue from highly fructose-fed rats and to delineate the effect of kinins and the angiotensin converting enzyme inhibitor ramipril in this animal model of glucose intolerance. DESIGN AND METHODS: Male Wistar rats (350 g body weight) were divided into four groups of 10 rats each: (1) controls; (2) oral ramipril at 500 microg/kg per day for the last 2 study weeks; (3) fructose in drinking water as a 10% (w/v) solution for 4 weeks; and (4) fructose + ramipril, with fructose administered as in group 3 plus the administration of ramipril for the last 2 study weeks. Systolic blood pressure (tail-cuff method), glucose tolerance (2 g/kg body weight intraperitoneally) and metabolic parameters were recorded. Kallikrein activity in tail artery and heart tissue homogenates was estimated at the end of the 4th study week from measurements of kininogenase activity and kinins generated by a radioimmunoassay. RESULTS: The area under the curve for the glucose tolerance test increased from 1265 +/- 103 mmol/l after 120 min in the control and 1152 +/- 36 mmol/l in the ramipril group (NS) to 2628 +/- 143 mmol/l in the fructose group (P<0.01). The administration of ramipril to fructose-treated rats in group 4 improved glucose tolerance (2160 +/- 100 mmol/l; P<0.05 versus group 3). Blood pressure increased significantly in fructose-fed rats but fell markedly in fructose-fed rats treated with ramipril (P<0.01). Kallikrein activity measured in the heart and vessels increased as a consequence of fructose administration (P<0.05), but the administration of ramipril increased this parameter to a much greater extent (P<0.01 versus control group), which correlated closely with the decrease in blood pressure and the improvement in glucose tolerance observed in the fructose + ramipril group. CONCLUSIONS: The administration of fructose as a solution in the drinking water induced glucose intolerance and increased blood pressure. Treatment with the angiotensin converting enzyme inhibitor ramipril improved glucose tolerance and significantly diminished blood pressure. Cardiovascular kinin-generating capability increased in treated animals and this increase was even higher when rats were treated with ramipril, suggesting that kinins, acting as a paracrine hormonal system, can exert cardiovascular protection and contribute to the beneficial effects of angiotensin converting enzyme inhibitor.

Enalapril: evaluación del efecto terapéutico / Enalapril: evaluation of therapeutic effect

Se comparó el efecto de una formulación farmacéutica de enalapril (ENA) con la del producto original (ORI) sobre la concentración de la enzima convertidora de angiotensina y la actividad de la renina plasmática en un grupo de voluntarios sanos y en un grupo de hipertensos, para validar su eficacia. A 5 voluntarios normotensos se les administró ENA durante 3 días y se determinó la concentración plasmática de la enzima convertidora de angiotensina y la actividad de renina plasmática a las 0, 5 y 53 horas. Esto se repitió a los 45 días pero con ORI. A 13 pacientes hipertensos esenciales se les determinó la concentración plasmática de la enzima convertidora de angiotensina y la actividad de renina plasmática basal y a la hora 1 y 4 de la administración de ENA. Luego se les administró ENA durante 90 días, al cabo de los cuales se repitieron los estudios iniciales. La actividad de la enzima convertidora de angiotensina disminuyó en los voluntarios con ambas formulaciones. Ante una dosis oral de ENA, los hipertensos descendieron sus niveles de la enzima convertidora de angiotensina y aumentaron los niveles de la actividad de renina plasmática. Las presiones sistólica y diastólica cayeron en los pacientes tratados con ENA durante 90 días con esfigmomanómetro. La presurometría ambulatoria mostró un descenso significativo de los valores tensionales diurnos y nocturnos, sin afectar el ritmo circadiano. Por lo tanto se considera que la utilización de ENA en la práctica clínica reproduce la eficacia del producto original

Enalapril: evaluación del efecto terapéutico / Enalapril: evaluation of therapeutic effect

Se comparó el efecto de una formulación farmacéutica de enalapril (ENA) con la del producto original (ORI) sobre la concentración de la enzima convertidora de angiotensina y la actividad de la renina plasmática en un grupo de voluntarios sanos y en un grupo de hipertensos, para validar su eficacia. A 5 voluntarios normotensos se les administró ENA durante 3 días y se determinó la concentración plasmática de la enzima convertidora de angiotensina y la actividad de renina plasmática a las 0, 5 y 53 horas. Esto se repitió a los 45 días pero con ORI. A 13 pacientes hipertensos esenciales se les determinó la concentración plasmática de la enzima convertidora de angiotensina y la actividad de renina plasmática basal y a la hora 1 y 4 de la administración de ENA. Luego se les administró ENA durante 90 días, al cabo de los cuales se repitieron los estudios iniciales. La actividad de la enzima convertidora de angiotensina disminuyó en los voluntarios con ambas formulaciones. Ante una dosis oral de ENA, los hipertensos descendieron sus niveles de la enzima convertidora de angiotensina y aumentaron los niveles de la actividad de renina plasmática. Las presiones sistólica y diastólica cayeron en los pacientes tratados con ENA durante 90 días con esfigmomanómetro. La presurometría ambulatoria mostró un descenso significativo de los valores tensionales diurnos y nocturnos, sin afectar el ritmo circadiano. Por lo tanto se considera que la utilización de ENA en la práctica clínica reproduce la eficacia del producto original (AU)

Kallikrein-like activity in nonpregnant and pregnant rat uterus, fetal membranes, placenta and amniotic fluid.

SBTI-resistant kininogenase activity was found in nonpregnant and pregnant rat uterus, placenta, amniotic fluid and fetal membranes. After trypsin treatment the kininogenase activity increased 2-3 fold. Total kininogenase (active plus inactive) was completely blocked by kallikrein antibodies. The physiological role of these kallikrein-like enzymes is unknown. It is speculated that these enzymes play a local role, perhaps in the processing of polypeptide hormones of through the release of kinins in the regulation of uterine blood flow.